• Worst Pills, Best Pills



• Health Letter



• Health Links



• Activist Courses



• Take Action!



• Drug Safety



• Healthcare Delivery



• Medical Devices



• Food Safety



• Occupational Health

Publications:

» (5/5/09) Petition to the FDA Requesting Enhanced Warnings for Amitiza (lubiprostone) (HRG Publication #1871) » (5/5/04) Testimony before FDA advisory committee concerning alosetron (Lotronex) (HRG Publication #1697) » (6/7/02) Allowing Lotronex Back on the Market Will Endanger Patients (HRG Publication #1622) » (4/23/02) Testimony Before FDA Advisory Committee Concerning Alosetron (LOTRONEX) (HRG Publication #1617) » (7/21/01) Letter to the FDA concerning tegaserod (Zelnorm), for constipation-predominant irritable bowel syndrome, and Novartis' reluctance to use ultrasound monitoring for their clinical trial subjects. (HRG Publication #1582) » (6/7/01) Letter to the Food and Drug Administration on a study stating a possible mechanism for the induction of ovarian cysts with the use of tegaserod (Zelmac) (HRG Publication #1577) » (4/18/01) Letter to the FDA concerning a memo from their Office of Post-marketing Drug Risk Assessment (OPDRA) that confirms and extends the dangers of the drug Lotronex (alosetron) for irritable bowel syndrome (HRG Publication #1566) » (3/22/01) Letter to the Food and Drug Administration urging that it not approve tegaserod (Zelmac) because of its highly questionable efficacy and its potential to cause ovarian cysts (HRG Publication #1561) » (12/9/00) Letter in Lancet on Alosetron for irritable bowel syndrome showing data manipulation in a company-sponsored clinical trial. (HRG Publication #1551) » (10/30/00) Letter to the Food and Drug Administration updating the number of cases of ischemic coliitis reported in our 8/31/00 petition. (HRG Publication #1544) » (8/31/00) Petition to the Food and Drug Administration to remove Lotronex from the market. (HRG Publication #1533) » (4/11/00) Letter to the Food and Drug Administration/FDA asking for the immediate withdrawal of Propulsid (cisapride) from the market. (HRG Publication #1519)

more resources

Because Public Citizen does not accept funds from corporations, professional associations or government agencies, we can remain independent and follow the truth wherever it may lead. But that means we depend on the generosity of concerned citizens like you for the resources to fight on behalf of the public interest. If you would like to help us in our fight, click here.